Agilent Technologies' Michael McMullen Has Sold $138.5M in Stock Over 266 Transactions
Michael McMullen, Director at Agilent Technologies, has executed 266 insider transactions totaling $138.5M in career stock sales with zero purchases, including a $7.8M single-day sale at $150/share.
Michael R. McMullen, Director at Agilent Technologies (A), has filed 266 insider transactions totaling $138.5 million in career stock sales with zero purchases. His most significant recent sale was a $7.8 million block trade of 52,297 shares at $150 per share in March 2024.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $138.5M |
| Career Buy Value | $0 |
| Total Transactions | 266 |
| Last Transaction | 2024-03-08 |
| Shares Remaining | 253,908 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2024-03-08 | Sell | 52,297 | $150.00 | $7.8M |
| 2023-12-13 | Exercise+Sell | 2,751 | $130.00 | $358K |
| 2023-12-07 | Exercise+Sell | 62,467 | $130.00 | $8.1M |
McMullen's selling pattern shows concentrated large-block dispositions rather than daily trickle sales. The December 2023 exercise-and-sell of 62,467 shares followed by the March 2024 $7.8M block suggests periodic monetization events, likely timed around vesting schedules or 10b5-1 plan execution windows.
What It Means
McMullen's $138.5M in career sales came entirely through systematic liquidation as a board member and former CEO of Agilent. Unlike many insiders who maintain token purchase activity, McMullen has made exactly zero open-market buys. The 266 transactions represent a methodical, multi-year conversion of equity compensation into cash.
With 253,908 shares still remaining, McMullen maintains a meaningful residual stake worth approximately $35M+ at current prices — a notable contrast to some insiders who sell down to near-zero. For Agilent investors, the key question is whether the current pause in selling since March 2024 reflects a deliberate hold or simply an exhausted tranche of exercisable options. The company's positioning in life sciences and diagnostics instruments remains strong, making the retained stake a potential positive signal.
What to Watch
- Whether McMullen resumes selling in 2026 after a nearly two-year pause
- Agilent's instrument demand recovery and China market rebound trends
- New option grants or equity awards that could trigger fresh selling activity
- Board composition changes that might affect McMullen's ongoing insider status
Breaking News Editor at 13F Insight. First to report on major SEC filings, institutional moves, and regulatory developments.
More from Alex →